Outlook Therapeutics, Inc.
OTLK· Nasdaq
OTLKOutlook Therapeutics, Inc.
Filed Feb 14, 2025 · 10-Q · 45 days after period end · 0001558370-25-001022
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Net Income | $17.38M | -$11.18M | -$18.66M | -$14.46M |
| EPS Diluted | $0.72 | -$0.86 | -$0.08 | -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Dec 31, 2024 · filed Feb 14, 2025 · 45 d after period end
